MISSION

Delivering Innovation for the Long-Term Complications of Venous Disease.

Our team is committed to transforming care for patients suffering from the long-term consequences of venous in-stent restenosis and native vessel occlusions, life-altering conditions that affect millions around the world.

The Board of Directors

Jeff Elkins
CEO

Jay Schmelter
RiverVest Venture Partners

Brad Vale PhD, DVM
Treo Ventures

Management Team

Our leadership team has deep roots in the peripheral vasculature, cardiovascular, aortic and neurovascular markets, with proven expertise in product development, regulatory affairs, quality and commercialization from both successful startups and leading medical device companies. We are committed to expanding the boundaries of innovation to improve patient care.

Jeff Elkins
CEO

Cathy Matthes
CFO

Eric Dooley
VP, Quality Assurance,
Clinical and Regulatory

John Giesen
VP, Marketing

Abha Chinubhai
VP, Research & Development and Operations

Alan Schuster
VP, Sales

Our Mission:

InterVene is focused on pioneering and delivering life-changing treatment options for patients suffering from the lasting consequences of venous disease. Together, our team and physician partners work to advance the interventional treatment for the persistent challenges related to venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.

Group photo

Our Values:

We are dedicated to improving patient lives by creating innovation solutions for large, underserved disease states. Our patient-centered foundation is built up on delivering best-in-class technology, pursuing excellence and building a strong culture.

Technology Infographic
Excellence Infographic
Culture Infographic
Patient Focus Infographic